市場調査レポート

バイオシミュレーション技術の世界市場

Biosimulation Technology

発行 Global Industry Analysts, Inc. 商品コード 341978
出版日 ページ情報 英文 164 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
バイオシミュレーション技術の世界市場 Biosimulation Technology
出版日: 2015年09月01日 ページ情報: 英文 164 Pages
概要

当レポートでは、バイオシミュレーション技術の世界市場を取り上げ、米国、カナダ、日本、欧州、アジア太平洋、ラテンアメリカ、およびその他の地域など、地域ごとの個別分析を行い、2013年から2020年に至る各年の実績/推定および予測を提供するとともに、主要企業およびニッチ企業42社のプロファイルをまとめています。

第1章 イントロダクション、調査方法、製品定義

  • 調査の信頼性とレポートの制約
  • 免責事項
  • データの解釈とレポート作成レベル
    • 定量技法および分析法
  • 製品の定義と調査範囲

第2章 エグゼクティブサマリー

  • 産業概要
    • バイオシミュレーション:薬剤の研究開発に大きなメリット
    • 現在および将来の分析
    • 応用分野とエンドユーザー分野
    • バイオシミュレーションは薬剤開発におけるパラダイムシフトを提供
    • 主な市場発展促進要因の概要
    • 市場発展阻害要因
    • 競争
  • 市場発展促進要因
    • 医療費の増加が創薬および薬剤開発ニーズを促進
    • CDDの発生件数および有病率の増加:主要な発展促進要因
    • 世界的な人口の高齢化が先進的な薬剤の研究開発を促す
    • 従来の創薬に関連した高いコスト
    • 臨床試験後期における高い失敗率
    • 最近の臨床試験後期における失敗例のリスト (2014年)
    • 中国とインド:研究開発投資のホットスポット
    • バイオシミュレーションは小児科創薬における課題を克服
  • 市場動向‐考察
    • シミュレーションツールは嵩む生命科学研究開発予算に対する圧力を取り除く
    • バイオシミュレーションは神経変性疾患を行き詰まりから引き出す
    • 糖尿病研究の新たな道筋を示す
    • バイオシミュレーションは開発支援から臨床ツールへと移行
    • 肺バイオシミュレーション:OIP開発に変革をもたらす
    • 薬剤再配置のためのバイオシミュレーション
    • グリッドベースドッキングがバイオシミュレーションを支援
    • より優れたモデルの必要性:市場における革新を促す主な要因
  • 技術概要
    • バイオシミュレーション:簡単な紹介
    • 創薬と薬剤開発
    • 薬剤開発プロセスの各段階
    • 薬剤開発技術
    • 人間生理学
    • 数学的モデルとバイオシミュレーション技法
    • ボトムアップモデリング
    • トップダウンモデリング
  • 製品の発表/認可
  • 最新産業動向
  • 主要な国際企業
  • 世界市場の展望

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • スペイン
    • ロシア
    • その他欧州
  • アジア太平洋
  • ラテンアメリカ
  • その他の地域

第4章 競合情勢

目次
Product Code: MCP-7920

This report analyzes the worldwide markets for Biosimulation Technology in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 42 companies including many key and niche players such as -

Advanced Chemistry Development, Inc.
Biovia
Certara L.P
Chemical Computing Group
Entelos, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Biosimulation: Massively Benefiting Drug R&D
  • Current and Future Analysis
  • Application and End-user Areas
    • Table 1: Global Biosimulation Market by Application (2014): Percentage Share of Revenue in Drug Development, Drug Discovery, and Others (includes corresponding Graph/Chart)
    • Table 2: Global Biosimulation Market by End-user Sector (2014): Percentage Share of Revenue for Academic Research Institutes, Biotechnology/Drug Companies, Contract Research Organizations (CROs), Regulatory Organizations, and Others (includes corresponding Graph/Chart)
  • Biosimulation Offers Paradigm Shift in Drug Development
  • Key Market Drivers in a Nutshell
  • Market Restraints
  • Competition

2. GROWTH DRIVERS

  • Increasing Healthcare Expenditure Drives the Need for Drug Discovery and Development
    • Table 3: Per Capita Healthcare Expenditure in US$ by Select Country (includes corresponding Graph/Chart)
    • Table 4: Healthcare Expenditure as % of GDP by Select Country (includes corresponding Graph/Chart)
  • Increasing Incidence and Prevalence of CDDs: A Major Growth Driver
    • Table 5: Worldwide Incidence of Cancer in Million: 2012, 2020 & 2030 (includes corresponding Graph/Chart)
    • Table 6: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart)
  • Aging Global Population Drives Advanced Drug R&D
    • Table 7: Global Population Statistics for the 65+ Age Group (2012) (includes corresponding Graph/Chart)
    • Table 8: Elderly Population (65+ Years) as a % of Total Population (2000 & 2025) (includes corresponding Graph/Chart)
  • High Costs Associated with Traditional Drug Discovery
    • Table 9: Escalating Costs of New Drug Development Over the Decades (includes corresponding Graph/Chart)
    • Table 10: US R&D Productivity Trends in Pharma Industry (2006- 2013) (includes corresponding Graph/Chart)
  • High Failure Rate of Late-Stage Drug Trials
  • List of Recent Late-stage Drug Failures (2014)
  • China and India: Hot Spots for R&D Investment
    • Table 11: Percentage Breakup of Global R&D Spending by Region (2012) (includes corresponding Graph/Chart)
  • Biosimulation Overcomes Challenges in Pediatric Drug Development

3. MARKET TRENDS - AN INSIGHT

  • Simulation Tools Take the Pressure off Mounting Life Science R&D Budgets
    • Table 12: Global Life Science R&D Expenditure (2011-2014): Total R&D Spending in US$ Billion (includes corresponding Graph/Chart)
  • Biosimulation Gets Neurodegenerative Disease Out of the Cul-de-sac
  • Marking New Avenues in Diabetes Research
  • Biosimulation Moving From Discovery Aid to Clinical Tool
  • Lung Biosimulation: Game Changer for OIP Development
  • Biosimulation for Drug Repositioning
  • Grid-based Docking Aids Biosimulation
  • Need for Better Models: A Major Factor Driving Innovation in the Market

4. TECHNOLOGY OVERVIEW

  • Biosimulation - A Brief Introduction
  • Drug Discovery and Development
  • Stages in Drug Development Process
    • Target identification
    • Target Validation
    • Lead Identification
    • Lead Optimization
    • Pre-Clinical Testing
    • Clinical Trials
  • Drug Discovery Technologies
  • Human Physiology
  • Mathematical Models and Biosimulation Technique
  • Bottom-up Modeling
  • Top-Down Modeling

5. PRODUCT LAUNCHES/APPROVALS

  • Certara Launches Simcyp In Vitro Analysis Toolkit Version 1.0
  • Optimata Granted US Patent for Biosimulation Technology
  • Cognigen Releases Version 1.3 of KIWI™
  • Simulations Plus Releases Version 9.0 of GastroPlus™
  • Certara Launches Version 2.0 of Cardiac Safety Simulator
  • Certara Releases Version 14 of Simcyp™ Simulator
  • Certara Receives FDA Grant for MechDermA
  • Physiomics Launches EasyAP™
  • Rhenovia Pharma Develops Simulator for Epilepsy Mechanisms
  • Insilico Biotechnology Launches Simulation Platform for Virtual Organs

6. RECENT INDUSTRY ACTIVITY

  • Certara Merges Its Pharsight Consulting with Quantitative Solutions
  • Optivia Biotechnology and Rhenovia Pharma Sign Partnership Agreement
  • Physiomics Signs Contract with Merck Serono
  • PMDA Equips Pharmacometrics Team with Certara's Biosimulation Solutions
  • CQDM and Alsace-Biovalley Collaborate on Biosimulation Platform
  • Dassault Systemes Acquires Accelrys
  • Rhenovia Pharma Secures Series B Funding
  • Pharmacelsus and Insilico Biotechnology Collaborate for Preclinical Drug Analysis
  • Arsenal Capital Partners Acquires Certara
  • Entelos Enters Into Licensing Agreement with USFDA

7. FOCUS ON SELECT GLOBAL PLAYERS

  • Advanced Chemistry Development, Inc. (Canada)
  • Biovia (Formerly Accelrys) (US)
  • Certara L.P. (US)
  • Chemical Computing Group (Canada)
  • Entelos, Inc. (US)
  • In Silico Biosciences, Inc. (US)
  • InhibOx (UK)
  • Insilico Biotechnology AG (Germany)
  • LeadInvent Technologies (India)
  • Leadscope, Inc. (US)
  • Nimbus Therapeutics (US)
  • OpenEye Scientific Software Inc. (US)
  • Physiomics Plc. (UK)
  • Rhenovia Pharma SAS (France)
  • Schrodinger, LLC (US)
  • Simulations Plus, Inc.(US)

8. GLOBAL MARKET PERSPECTIVE

    • Table 13: World Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 14: World 8-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2013, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Biosimulation to Abate Life Sciences R&D Spending
    • Table 15: The US Life Science Industry Annual R&D Expenditure: 2011-2014 (includes corresponding Graph/Chart)
    • Ageing Population - Booster for Effective Drug Development
    • Table 16: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Rise in Chronic Disorders Drive Market Growth
    • Table 17: US Diabetics Population (2010-2017): Percentage Population with Diagnosed and Undiagnosed Diabetes (includes corresponding Graph/Chart)
    • Table 18: High Blood Pressure Prevalence in the US (2012): Prevalence Rates for Male and Female Population by Age Groups (includes corresponding Graph/Chart)
    • Table 19: High Blood Pressure Prevalence in the US (2012): Prevalence Rates for Male and Female Population by Ethnic Group (includes corresponding Graph/Chart)
    • Table 20: New Cancer Cases in the US by Gender and Affected Site: 2014E (includes corresponding Graph/Chart)
    • Product Launches
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 21: The US Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Increasing Incidence of Cancer: A Major Growth Driver
    • Table 22: New Cancer Cases in Canada by Gender and Affected Site: 2014E (includes corresponding Graph/Chart)
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 23: Canadian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Graying Population Spurs Demand for Advanced Drug Development
    • Table 24: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 25: Japanese Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Regulatory Authorities Stress on Paradigm Shift in Drug Development
    • Ageing Population Boosts Demand
    • Table 26: European Country-wise Statistics of 60+ Population as % of Total Population: 2013 (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 27: European Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 28: European 8-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2013, 2015 & 2020 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Strategic Corporate Developments
    • Rhenovia Pharma SAS - A Key Player
  • B. Market Analytics
    • Table 29: French Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Product Launch
    • Strategic Corporate Development
    • Insilico Biotechnology AG - A Key Player
  • B. Market Analytics
    • Table 30: German Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 31: Italian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4d. UNITED KINGDOM

  • A. Market Analysis
    • Product Launch
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 32: The UK Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 33: Spanish Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analysis
    • Table 34: Russian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • Market Analysis
    • Table 35: Rest of European Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Growing Population and Aging Demographic Drive Demand for Advanced Drug Development
    • Table 36: Population Statistics in Asia (Including Japan) & Percentage of Population Aged Above 65 Years (includes corresponding Graph/Chart)
    • Leadinvent Technologies (India) - A Key Player
  • B. Market Analytics
    • Table 37: Asia-Pacific Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

6. LATIN AMERICA

  • Market Analysis
    • Table 38: Latin American Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

7. REST OF WORLD

  • A. Market Analysis
    • Product Launch
  • B. Market Analytics
    • Table 39: Rest of World Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top